This preprint reports "high clinical benefit" of ivermectin + mebendazole in cancer patients. However, the study authors themselves state 'benefit cannot be inferred' due to design limitations.
Let's unpack why.
🚨You asked and we delivered - CURB2 Ph3 RCT now allows those assigned to SOC to have the flexibility to stay on same systemic therapy➡️real world practice.
Please consider opening/accruing this trial🙏
@NRGonc@CDNCancerTrials@DrMengWelliver
We’re hiring! Radiation Oncologist opportunity at Penn State Health
Join a growing, collaborative team delivering cutting-edge, patient-centered cancer care across a leading academic health system.
👉 Apply here: https://t.co/7gIIq4J48T
Pleased to share our recently published ASTRO consensus paper in Practical Radiation Oncology on DVH dose constraints for radiation therapy treatment planning, led by my friend Dr. Lindsay Puckett.
https://t.co/IWqckLZF2B
A thread on the goals of this effort 🧵
#RadOnc#ASTRO
Localized prostate cancer management is NOT one-size-fits-all. 🎯
From low-risk to very high-risk and cN1 disease, treatment decisions hinge on risk stratification, imaging, and timing of ADT.
These guideline algorithms bring clarity to:
🟢 Active surveillance vs radical treatment
🟡 Favorable vs unfavorable intermediate risk
🔴 High-risk, very high-risk, and cN1 disease
🔁 Post-treatment PSA monitoring and salvage pathways
📸 BCR workup with PSMA PET-CT and MRI
📘 Evidence-based. Structured. Practical.
🔖 Save for clinics
📤 Share with your unit
@myesmo@esmo_open@OncoAlert@ASCO@ASTRO_org
#OncoTwitter #MedTwitter #ProstateCancer #UroOnc #RadiationOncology #MedicalOncology #GUOncology
Ever had a case of spurious postop PSA elevation that didn’t make sense? Hint: recheck the PSA with human anti-mouse antibody (HAMA) treatment. Here’s a case where a patient was spared from unnecessary salvage therapy.
☢️New meta-analysis in JAMA Network Open:
🎯Stereotactic body radiotherapy (SBRT) alone for oligometastatic cancer achieved 70% systemic therapy-free survival at 1-2 years, highest in renal (87%) and prostate cancer (78%).
🎯Low toxicity rates suggest SBRT may safely defer chemotherapy in selected patients.
10.1001/jamanetworkopen.2025.49685
@OncoAlert@DrYukselUrun #MedX #Cancer #Oncology @JAMANetworkOpen
Don’t want to just data dump a bunch of kidney SBRT papers on ya rn (sorry I am enthusiastic about this topic) but in general even for niche solitary kidney scenarios fantastic results median eGFR decline around 13 ml/min plateaus at 2 years so it’s a fantastic option especially for peri-hilar or > 2-3 cm not suitable for thermal ablation as most patients motivated to avoid HD, also associated with 99% 5y local control
Proud of our Radiation Oncology team for giving back to our community.
Together, we donated 141 lbs of food to the Hershey Food bank—helping support families in need and making a meaningful impact beyond the clinic. @PennStHershey
🎗️October is Breast Cancer Awareness Month. Radiation treatment is more than a therapy - it's a step toward healing and renewed hope. Every beam is aimed at a future free from cancer. To everyone walking this path; your strength inspires us all. 💗@PennStHershey
📢 Excited to welcome @VinitaTakiar, the new Chair of the Department of Radiation Oncology! We’re excited for the leadership, expertise, and vision Dr. Takiar brings to our team. #Welcome#RadOnc@PennStHershey
🧵1/
🚨New case report out in Cureus:
Face the Pain: Radiobiological and Clinical Considerations of Re-radiosurgery to the Trigeminal Nerve
👉 A deep dive into a unique case of medically refractory TGN in the setting of a petroclival meningioma.
🔗 https://t.co/jxckq1rugm